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Background-—Early withdrawal of recommended antiplatelet treatment with clopidogrel adversely affects prognosis following
percutaneous coronary interventions. Optimal antiplatelet treatment is essential following ST-segment elevation myocardial
infarction (STEMI) given the increased risk of thrombotic complications. This study assessed the frequency, predictors, and clinical
impact of early prasugrel cessation in patients with STEMI undergoing primary percutaneous coronary interventions.
Methods and Results-—We pooled patients with STEMI discharged on prasugrel in 2 prospective registries (Bern PCI Registry
[NCT02241291] and SPUM-ACS (Inﬂammation and Acute Coronary Syndromes) [NCT01000701]) and 1 STEMI trial
(COMFORTABLE-AMI (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction) [NCT00962416]).
Prasugrel treatment status at 1 year was categorized as no cessation; crossover to another P2Y12-inhibitor; physician-
recommended discontinuation; and disruption because of bleeding, side effects, or patient noncompliance. In time-dependent
analyses, we assessed the impact of prasugrel cessation on the primary end point, a composite of cardiac death, myocardial
infarction, and stroke. Of all 1830 included patients (17% women, mean age 59 years), 83% were treated with new-generation
drug-eluting stents. At 1 year, any prasugrel cessation had occurred in 13.8% of patients including crossover (7.2%),
discontinuation (3.7%), and disruption (2.9%). Independent predictors of any prasugrel cessation included female sex, age, and
history of cerebrovascular event. The primary end point occurred in 5.2% of patients and was more frequent following
disruption (hazard ratio 3.04, 95% conﬁdence interval,1.34–6.91; P=0.008), without signiﬁcant impact of crossover or
discontinuation. Consistent ﬁndings were observed for all-cause death, myocardial infarction, and stent thrombosis following
prasugrel disruption.
Conclusions-—In this contemporary study of patients with STEMI, early prasugrel cessation was not uncommon and primarily
involved change to another P2Y12-inhibitor. Disruption was the only type of early prasugrel cessation associated with statistically
signiﬁcant excess in ischemic risk within 1 year following primary percutaneous coronary interventions. ( J Am Heart Assoc.
2018;7:e008085. DOI: 10.1161/JAHA.117.008085.)
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F low restoration in the infarct-related artery by means ofpercutaneous coronary intervention (PCI) and dual
antiplatelet therapy (DAPT) for potent platelet inhibition are
the cornerstones for management of patients with acute ST-
segment–elevation myocardial infarction (STEMI).1,2 Com-
pared with clopidogrel, prasugrel provides rapid-onset, more
potent and consistent inhibition of platelet aggregation,3
and reduces the risk of cardiovascular mortality and
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stent thrombosis in patients with myocardial infarction
(MI).4 Prasugrel is recommended over clopidogrel following
primary PCI1,2 and is used increasingly in real-world clinical
practice.5
Nonadherence to recommended antiplatelet therapy fol-
lowing PCI is not uncommon and increases the risk of adverse
ischemic events.6–8 Notably, different modes of DAPT cessa-
tion (either driven by physician recommendation, patient
noncompliance, or interventions necessitating temporary
treatment withdrawal) appear to have varying effects on
patient outcomes.6 Previous studies assessing premature
cessation of antiplatelet therapy focused primarily on more
stable clinical settings and clopidogrel rather than novel, potent
P2Y12-inhibitors, and they often did not account for the
temporal relation between treatment cessation and subse-
quent outcomes.9,10 While STEMI is characterized by elevated
ischemic risk compared with stable coronary artery disease
(CAD) and is an independent predictor of stent thrombosis,11
there are limited data on the adherence to guideline-
recommended antiplatelet treatment following primary PCI.
Moreover, although certain aspects of prasugrel treatment
might adversely affect long-term compliance, including greater
treatment cost or accentuated risk of bleeding, little is known
about adherence to prasugrel in patients with STEMI. Against
this background, we sought to address the incidence, under-
lying reasons, and clinical impact of early prasugrel cessation in
a sizable, contemporary cohort of patients with STEMI treated
by current standards (ie, primary PCI with predominantly new-
generation drug-eluting stents [DES]).
Methods
The data, analytic methods, and study materials cannot be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure, given
constraints in broader sharing of the data.
Patient Population
For the present study, we pooled patients with STEMI with the
same qualifying diagnostic criteria who were included in the
prospective Bern PCI Registry (NCT02241291), SPUM-ACS
(Inﬂammation and Acute Coronary Syndromes) registry
(NCT01000701), or COMFORTABLE-AMI (Comparison of
Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction
(STEMI)) trial (NCT00962416); were treated by means of PCI;
and discharged on prasugrel. Details are presented in Data
S1. Brieﬂy, all patients undergoing PCI at Bern University
Hospital, Switzerland as of 2009 have been prospectively
entered into the Bern PCI Registry.12,13 There are no formal
exclusion criteria, and all patients providing informed consent
for prospective follow-up are included. The SPUM-ACS cohort
study is a multicenter, observational cohort study of patients
presenting with acute coronary syndromes (ACS) at 4 Swiss
tertiary centers with minimal exclusion criteria (severe
physical disability, inability to comprehend study require-
ments, and estimated life expectancy <1 year).14 The
COMFORTABLE AMI trial was a multicenter, randomized
controlled trial (RCT) comparing a biodegradable polymer–
based biolimus-eluting stent with a bare-metal stent for
primary PCI. Main exclusion criteria were mechanical compli-
cations of acute MI, use of vitamin-K antagonists, planned
surgery (unless uninterrupted DAPT during the perisurgical
period was judged feasible), and history of bleeding
diathesis.15 The studies complied with the Declaration of
Helsinki and were approved by local institutional ethics
committees. All patients provided written, informed consent.
Procedures
PCI was performed in accordance with current practice
guidelines.2 Thrombus aspiration was recommended in all
patients whenever deemed technically feasible (COMFORTA-
BLE-AMI) or whenever thrombus was angiographically visible
(registry patients). In the COMFORTABLE-AMI trial, patients
were randomly assigned to treatment with biolimus-eluting
stents (BioMatrix, Biosensors Europe SA, Morges, Switzer-
land) or bare-metal stent (Gazelle, Biosensors Europe SA). In
registry patients, the use of a newer-generation DES was
recommended with ﬁnal selection of stent type left at the
discretion of the operator. Periprocedural management,
Clinical Perspective
What Is New?
• In a contemporary population of patients treated with primary
percutaneous coronary intervention, early (before 1 year)
cessation of prasugrel treatment was not uncommon and
more frequently consisted of switching to clopidogrel.
• Early prasugrel cessation was associated with signiﬁcantly
increased risk of downstream ischemic events only in the
context of disruption (ie, premature cessation because of
bleeding, side effects, or patient noncompliance).
What Are the Clinical Implications?
• The increased risk of subsequent ischemic events should be
considered when prasugrel is stopped early because of a
bleeding event or noncompliance.
• Future studies should explore whether shorter than cur-
rently recommended duration of prasugrel treatment might
be an acceptable option in properly selected patients with
ST-segment elevation myocardial infarction undergoing
primary percutaneous coronary intervention.
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including dose of unfractionated heparin or use of glycopro-
tein IIb/IIIa inhibitors, was left to the operators’ discretion.
DAPT consisting of aspirin and a P2Y12-inhibitor was initiated
before, at the time of, or immediately after the procedure. The
recommended treatment duration was 1 year for prasugrel
and lifelong treatment for aspirin for both RCT and registry
patients. Prasugrel administration was discouraged in patients
with prior cerebrovascular events. Recommended mainte-
nance dose for prasugrel was 10 mg, or 5 mg in patients with
age >75 years or body weight <60 kg.
Patient Follow-Up
Patients were prospectively followed throughout 1 year after
PCI to assess adverse cardiac and cerebrovascular events in
all 3 studies. Survival data were obtained from hospital
records and municipal civil registries. A health questionnaire
was sent to all living patients with questions on rehospi-
talization, medical treatment, and adverse events, followed
by telephone contact in case of missing response. General
practitioners, referring cardiologists, and patients were
contacted, and external medical records, discharge letters,
and coronary angiography documentation were systemati-
cally reviewed for additional information in case of potential
events or any change in P2Y12-inhibitor therapy. Indepen-
dent study monitors veriﬁed source data according to a
prespeciﬁed monitoring plan. Identical case record forms
were used for all patients in the 2 registries as well as the
RCT, and all data were stored in the same central database
(Cardiobase, 2mT, Ulm, Germany). Medical treatment was
recorded during index PCI, at discharge, and at 1 year.
Adherence to prasugrel, date, and patient-reported reasons
for cessation were speciﬁcally assessed via telephone
interview or clinical visit at 1 year; in addition, all medical
reports were screened for medication status. Because
protocol-recommended duration of P2Y12-inhibitor treatment
was 1 year (unless recurrent ischemic events triggered
longer continuation), we considered 330 days or more of
treatment as adherence.
Adjudication of cessation events was done centrally for
all patients included in the pooled data set. Prespeciﬁed
categories of prasugrel treatment status at 1 year included
no cessation (continuous 1-year treatment) or cessation
(any stop before 1 year). Cessation was classiﬁed as
(1) crossover to another P2Y12-inhibitor (clopidogrel or tica-
grelor); (2) physician-recommended discontinuation (because
of initiation of oral anticoagulation, surgery/intervention, or
unspeciﬁed physician decision); and (3) disruption because
of bleeding, perceived side effects, or patient noncompli-
ance. Discontinuation and disruption were deﬁned similarly
to the PARIS (Patterns of Non-Adherence to Antiplatelet
Regimens in Stented Patients) study.6 Because of the
potential for de-escalation from prasugrel to a less-potent
antiplatelet agent, we also recorded crossover that was not
reported in PARIS (which included 92% clopidogrel-treated
patients). Moreover, because timing of possible re-initiation
of prasugrel was not captured in this population, we were
unable to deﬁne interruptions (deﬁned as cessation for up
to 14 days because of surgery in PARIS); temporary
cessations because of surgery or other interventions were
included under physician-decided discontinuation in our
analysis. First cessation events are reported, such that
some patients with cessation were receiving prasugrel at
1 year because of subsequent re-initiation.
Clinical End Points and Study Assessments
Clinical events were adjudicated by an independent clinical
events committee for each study. Because 1 center (Bern
University Hospital, Bern, Switzerland) had the leading role for
planning, coordination, and execution of all 3 studies,
outcome deﬁnitions were identical and event adjudication
was done in a consistent, comparable manner for all patients
included in the 3 studies. Cardiac death was deﬁned as any
death from an immediate cardiac cause, procedure-related
mortality, and death of unknown cause. Deﬁnitions of
spontaneous and periprocedural MI are detailed in Data S1.
Stent thrombosis was deﬁned according to the Academic
Research Consortium deﬁnitions.16 Bleeding was categorized
according to Bleeding Academic Research Consortium as well
as Thrombolysis in Myocardial Infarction criteria.17 For the
present analysis, the primary end point was a composite of
cardiac death, nonfatal MI, and stroke. The key secondary end
point was the composite of cardiac death, MI, stroke, target-
vessel revascularization, and deﬁnite or probable stent
thrombosis.
Statistical Analyses
Continuous variables are summarized as meanSD and
categorical ones as numbers (percentages). P values for
between-group comparisons are based on t tests, Fisher exact
tests, and v2 tests as appropriate. Lesion characteristics were
compared using mixed linear, logistic, and multinomial
regression models accounting for multiple lesions per patient.
Kaplan–Meier curves were constructed for time to prasugrel
cessation. Predictors of early prasugrel cessation were
modeled using Cox models and those predictors with
signiﬁcant relationship (P<0.2) were evaluated for inclusion
into a multivariate model; predictors with P<0.15 inside the
multivariable model were ﬁnally retained. Using Cox models
with time-varying covariates, we examined the effect of
prasugrel cessation on clinical outcomes. For patients with
any of the 3 types of early cessation (discontinuation,
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crossover, or disruption), the follow-up time was split into 2
periods, before versus after the ﬁrst recorded given type of
cessation; events occurring in patients without cessation or
before treatment cessation were used as reference, and no
other covariates were included. Results are presented as
hazard ratios (HR) with corresponding 95% conﬁdence
intervals (CI). For all clinical events, expected numbers were
calculated as number of events divided by the HR (compared
with the reference of being on prasugrel treatment). Analyses
were performed in Stata 14.2.
Results
Baseline Characteristics
Of all 4454 patients with STEMI enrolled between October
2009 and June 2014, 1953 were discharged on prasugrel and
1830 patients were ﬁnally included in the present analysis
(Figure 1). Clinical follow-up at 1-year post-PCI was available
for all but 3 patients (Table S1). Within 1 year, any cessation
of prasugrel had occurred in 252 patients (13.8%). Patterns of
cessation included crossover (7.2%), physician-recommended
discontinuation (3.7%), and disruption (2.9%). Crossover
included switching primarily to clopidogrel or, less frequently,
ticagrelor (83.1% versus 8.5% of patients in the crossover
group were on clopidogrel versus ticagrelor at 1 year,
respectively; Table S2). The time course of different types of
prasugrel cessation is summarized in Figure 2, indicating
earlier crossover versus more delayed discontinuation or
disruption (median time with 25% to 75% interquartile range
31 [10–115] versus 207 [120–291] versus 158 [62–250]
days, respectively).
Baseline characteristics are summarized in Table 1. Com-
pared with patients with no early cessation, those with
crossover to clopidogrel or ticagrelor were older, more
frequently female with a history of cerebrovascular event,
and less frequently had insulin-treated diabetes mellitus.
Moreover, history of malignancy and anemia were more
Figure 1. Summary of study ﬂow. APT indicates antiplatelet therapy; PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation
myocardial infarction.
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frequent in patients with discontinuation. We found no
substantive differences with respect to professional back-
ground, marital status, and educational level (Table S3).
Patients with crossover were more commonly treated with
new-generation DES and less frequently with bare-metal stent
(Table 2). Independent predictors of any early cessation
included female sex, history of cerebrovascular event, and age
(Table 3 and Table S4).
Reasons for Prasugrel Cessation
Patient-reported reasons for early prasugrel cessation are
illustrated in Figure 3. Leading reasons for crossover included
unspeciﬁed reason, oral anticoagulation initiation, bleeding,
interventions, and perceived side effects. Reasons for
discontinuation were unspeciﬁed physician recommendation,
oral anticoagulation initiation, and interventions. Leading
reasons for disruption were patient preference, bleeding, side
effects, and treatment cost (Figure 3).
Clinical Outcomes in Relation to Early Prasugrel
Cessation
At 1 year, the primary end point had occurred in 95 patients
(5.2%) (Table 4). Figure 4 summarizes 1-year clinical out-
comes in patients without cessation (reference) compared
with events occurring after any type of early prasugrel
cessation. The primary end point occurred more frequently
following disruption (HR: 3.04, 95% CI, 1.34–6.91; P=0.008).
Differences were consistent for the key secondary end point
(HR: 2.39, 95% CI, 1.12–5.10; P=0.03), all-cause death (HR:
8.08, 95% CI, 3.05–21.37; P<0.001), cardiac death (HR: 7.35,
95% CI, 2.48–21.80; P<0.001), MI (HR: 4.00, 95% CI, 1.61–
9.94; P=0.003), and deﬁnite or probable stent thrombosis
(HR: 2.96, 95% CI, 1.08–8.12; P=0.03). No signiﬁcant
differences were observed following discontinuation or cross-
over for the primary or secondary end points. There was no
association between early treatment cessation and subse-
quent bleeding events (Figure S1). Table S5 summarizes
individual primary end point events following any mode of
early prasugrel cessation. Median time from prasugrel cessa-
tion to ﬁrst primary end point event was 10 days following
crossover, 35 days following discontinuation, and 8 days
following disruption.
Sensitivity Analyses: RCT Versus Registry
Patients
Patients enrolled in the RCT (n=484, 26.4%) had a lower rate
of prior PCI and less frequently presented with Killip class IV,
with otherwise nondiffering baseline characteristics compared
with patients enrolled in the registries (n=1346, 73.6%)
(Table S6). The frequency of overall vprasugrel cessation as
well as of each type of cessation did not differ signiﬁcantly
between patients enrolled in the RCT versus the registries
(Table S7). Consistent with the ﬁndings in the entire pooled
population, disruption, but not crossover or discontinuation,
was associated with higher risk of the primary and secondary
Figure 2. One-year Kaplan–Meier plots of crossover, physician-recommended discontinuation, and
disruption of prasugrel throughout 1 year.
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end points, MI, all-cause and cardiac mortality at 1 year in a
sensitivity analysis focusing only on patients included in the
registries (Figure S2).
Discussion
While current recommendations advocate DAPT for 1 year
following acute MI, there is limited evidence regarding
adherence to prasugrel—one of the preferred antiplatelet
agents in this context. This study assessed the incidence,
reasons, and clinical impact of early prasugrel cessation in
a sizable, contemporary cohort of patients with STEMI
treated with PCI by current standards. Prasugrel cessation
before 1 year was not uncommon (14%), but was less
frequent compared with previous studies focusing on any
DAPT cessation post-PCI in more stable clinical settings.6–10
Crossover to another P2Y12-inhibitor, mainly clopidogrel,
was more frequent compared with physician-recommended
discontinuation or disruption (because of bleeding, side
effects, or noncompliance). Clinical characteristics previously
linked to higher bleeding risk18 were more common in
patients who stopped prasugrel, suggesting that concerns
about bleeding likely inﬂuenced decision-making regarding
antiplatelet management. Even though the rate of major
adverse cardiac events was numerically higher following
discontinuation, disruption was the only mode of early
prasugrel cessation associated with a statistically signiﬁcant
adverse impact on subsequent cardiovascular outcomes.
Rapid mechanical reperfusion with coronary stenting and
potent adjunctive antithrombotic treatment are the principles
for optimal management of patients with STEMI. Prasugrel, a
potent and rapid-acting thienopyridine, is more effective than
clopidogrel for prevention of ischemic events in patients with
MI including those with STEMI.4,19 Current guidelines
recommend 12-month DAPT consisting of aspirin and a
P2Y12-inhibitor, preferably prasugrel or ticagrelor unless
contraindicated.1,2 In this study, 86% of patients with STEMI
remained on continuous prasugrel treatment within 1 year
Table 1. Baseline Clinical Characteristics
No Cessation
(n=1578)
Crossover
(n=131)
Discontinuation
(n=67)
Disruption
(n=54)
P Value (vs No Cessation)
Crossover Discontinuation Disruption
Age 58.910.7 61.211.5 60.913.3 59.911.7 0.02 0.14 0.49
Female sex 247 (15.7) 38 (29.0) 20 (29.9) 7 (13) <0.001 0.004 0.71
BMI 27.44.2 26.84.0 26.34.4 27.24.3 0.11 0.04 0.66
Current smoking 748 (48.0) 58 (44.3) 28 (43.8) 28 (52.8) 0.47 0.53 0.58
Hyperlipidemia 799 (51.1) 75 (57.3) 36 (53.7) 25 (47.2) 0.20 0.71 0.58
Hypertension 733 (46.6) 65 (49.6) 23 (34.3) 19 (35.2) 0.52 0.06 0.13
Diabetes mellitus 212 (13.5) 11 (8.4) 6 (9) 6 (11.1) 0.11 0.36 0.84
Insulin-dependent 50 (3.2) 0 (0) 2 (3.0) 2 (3.7) 0.03 1.00 0.69
Family history of CAD 403 (25.9) 37 (28.5) 14 (20.9) 8 (15.1) 0.53 0.39 0.08
Renal dysfunction* 113 (8.1) 12 (10.4) 7 (10.9) 3 (6.3) 0.38 0.36 1.00
Peripheral artery disease 35 (2.2) 2 (1.5) 0 (0) 1 (1.9) 1.00 0.40 1.00
History of cerebrovascular event 9 (0.6) 4 (3.1) 1 (1.5) 0 (0) 0.01 0.34 1.00
Previous PCI 135 (8.6) 11 (8.4) 2 (3.0) 3 (5.6) 1.00 0.12 0.62
Previous CABG 27 (1.7) 1 (0.8) 0 (0.0) 0 (0) 0.72 0.62 1.00
Time from symptom onset to
balloon inflation (min)
226 (159; 385) 244 (157; 465) 259 (165; 562) 228 (156; 377) 0.38 0.09 0.95
Killip class IV at presentation 76 (4.8) 8 (6.2) 3 (4.5) 0 (0) 0.52 1.00 0.18
LVEF (%) 48.011.1 46.411.6 44.412.0 51.19.2 0.16 0.02 0.06
History of malignancy 66 (4.2) 0 (0) 10 (14.9) 4 (7.4) 0.008 0.001 0.29
Anemia† 162 (12.3) 13 (11.7) 12 (21.1) 1 (2.4) 1.00 0.06 0.05
Thrombocytopenia‡ 32 (2.4) 1 (0.9) 1 (1.8) 1 (2.4) 0.51 1.00 1.00
Data are summarized as meanSD, median (25–75% interquartile range), or count (%). BMI indicates body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.
*Deﬁned as estimated glomerular ﬁltration rate <60 mL/min per 1.73 m² using the Cockcroft-Gault formula.
†Hemoglobin <130 g/L for men or <120 g/L for women.
‡Thrombocytes <150 g/L.
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following PCI. Considering that more than half of early
prasugrel cessations involved switching to another P2Y12-
inhibitor and in conjunction with high adherence to aspirin,
our ﬁndings show adherence to guideline-recommended DAPT
duration in >90% of patients. This ﬁnding likely reﬂects
appreciation of the persistently elevated ischemic risk
following acute STEMI. Previous investigations reported
higher rates of early DAPT cessation within 1 year post PCI,
ranging between 18.5% and 24%,6–10 but this needs to be
interpreted in view of different study populations (primarily
stable patients with CAD) and antiplatelet treatments (mostly
clopidogrel) as well as varying deﬁnitions of treatment
cessation across studies.
Analyses of correlates and underlying reasons for prasugrel
cessation provided additional important insights. Crossover to
clopidogrel—the most common pattern of cessation—oc-
curred more frequently among older, female patients with a
history of malignancy or prior cerebrovascular event (ie, a
formal contraindication for prasugrel). Age and female sex
previously emerged as independent predictors of bleeding in
prasugrel-treated patients.18 Along these lines, it is important
to note that the superior efﬁcacy of prasugrel over clopidogrel
for reduction of ischemic events was coupled with excess
bleeding in the overall population,4 but not in the prespeciﬁed
STEMI subanalysis of the TRITON-TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis In Myocardial Infarc-
tion 38) trial.19 The ﬁnding that oral anticoagulation initiation
was a main reason for crossover or discontinuation is
consistent with evidence of unacceptably high bleeding risk
attributed to triple antithrombotic therapy including
prasugrel.20 Collectively these ﬁndings likely reﬂect physician
consideration of bleeding risk factors that may have led to
Table 2. Procedural Characteristics
No Cessation
(n=1578)
Crossover
(n=131)
Discontinuation
(n=67)
Disruption
(n=54)
P Value (vs No Cessation)
Crossover Discontinuation Disruption
Number of lesions 2219 189 99 82
Lesions treated per patient 1.410.73 1.440.81 1.480.81 1.520.77 0.59 0.40 0.27
Multivessel treatment 174 (11.) 17 (13) 10 (15.2) 8 (14.8) 0.47 0.32 0.38
Treated vessels
Left main coronary artery 28 (1.8) 3 (2.3) 0 (0) 0 (0) 0.73 0.62 1.00
Left anterior descending artery 748 (47.5) 66 (50.4) 39 (59.1) 27 (50) 0.53 0.08 0.78
Left circumflex artery 301 (19.1) 22 (16.8) 13 (19.7) 6 (11.1) 0.56 0.87 0.16
Right coronary artery 676 (42.9) 59 (45) 25 (37.9) 29 (53.7) 0.65 0.45 0.13
Saphenous vein graft 9 (0.6) 0 (0) 0 (0) 0 (0) 1.00 1.00 1.00
Number of stents per lesion 1.330.61 1.320.60 1.330.61 1.300.65 0.89 0.97 0.73
Type of stent per lesion*
First-generation DES 27 (1.3) 1 (0.6) 0 (0) 0 (0) 0.42 0.62 0.62
New-generation DES 1740 (82.9) 158 (89.3) 62 (73.8) 62 (80.5) 0.04 0.09 0.65
BMS 339 (16.2) 17 (9.6) 22 (26.2) 16 (20.8) 0.03 0.05 0.36
Total stent length per lesion (mm) 27.214.6 29.116.1 25.312.9 26.212.5 0.10 0.27 0.57
Minimum stent diameter per lesion (mm) 3.050.52 3.040.51 3.030.51 3.050.48 0.84 0.97 0.96
Thrombus aspiration 890 (40.3) 75 (39.9) 34 (35.1) 31 (37.8) 0.93 0.33 0.68
Bifurcation lesion (any lesion) 229 (14.5) 22 (16.8) 11 (16.7) 8 (14.8) 0.52 0.60 1.00
Long lesion† 249 (23.6) 19 (23.8) 7 (16.7) 11 (28.9) 1.00 0.36 0.44
BMS indicates bare-metal stent; DES, drug-eluting stent.
*First-generation DES: Cypher, Endeavour. Totals for types of stent do not sum up to the number of total stents, because 7 lesions were treated with both new-generation DES and BMS.
†Any total stent length ≥20 mm.
Table 3. Multivariate Predictors of Any Prasugrel Cessation
n HR (95% CI) P Value
Female sex 1619 1.63 (1.20–2.23) 0.002
History of cerebrovascular
event
1619 3.88 (1.44–10.46) 0.007
Age (per 10 y) 1619 1.15 (1.02–1.31) 0.024
CI indicates conﬁdence interval; HR, hazard ratio.
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change from prasugrel to a less-potent antiplatelet agent.
Conversely, with the exception of insulin-treated diabetes
mellitus, we did not observe a greater cluster of well-
recognized “ischemic” risk factors (eg, smoking, prior MI or
PCI, graft stenting, and disease complexity21) in patients who
remained on prasugrel during 1 year.
Previous studies assessing clinical outcomes in relation to
early DAPT cessation in more stable clinical settings have
yielded conﬂicting results. Several reports found no adverse
impact of DAPT interruptions after 30 days post PCI with new-
generation DES9,10; these studies, however, pooled all DAPT
interruptions between 30 days and 12 months, thereby not
accounting for the possibly differing ischemic risk throughout
the entire period following the ﬁrst month post-PCI. Other
studies applying time-dependent analyses reported higher risk
of ischemic events following early DAPT cessation7,8 and
importantly showed that the clinical sequelae depend on the
underlying reason and mode of cessation.6 Our present
ﬁndings extend these observations in the very high-risk
setting of patients with STEMI by demonstrating a lack of
association between prasugrel discontinuation or crossover
and greater ischemic risk. In contrast, prasugrel disruption
was associated with 3-fold higher risk of major ischemic
adverse events and consistently higher rates of mortality and
stent thrombosis. Although direct comparisons are hindered
by differing end point deﬁnitions, the incremental risk of
major ischemic events following prasugrel disruption in STEMI
appears to be greater compared with the respective risk
following DAPT disruption in stable CAD or ACS patients in the
PARIS registry6 (HR 2.97 in this study versus 1.5 in PARIS).
Notwithstanding these associations disfavoring disruption,
early prasugrel cessation (by any mode) accounted for only a
small proportion of all ischemic events within the ﬁrst year
following STEMI, since >80% of these events occurred on
prasugrel treatment.
The leading cause of prasugrel disruption was cessations
because of unjustiﬁed patient decision (ie, noncompliance).
We did not detect clinical characteristics that could allow
early identiﬁcation of these patients. In view of the adverse
clinical impact of disruption, our ﬁndings emphasize the need
to continuously promote patient education and enhance
compliance with recommended antiplatelet treatment follow-
ing STEMI. Moreover, the link between bleeding, prasugrel
disruption, and increased risk of downstream ischemic events
in this study substantiates the concept that bleeding compli-
cations adversely impact long-term PCI outcomes at least in
part by triggering early withdrawal of recommended anti-
platelet treatment.
Recent recommendations advocate 12-month adherence
to the combination of aspirin plus a (preferably potent) P2Y12-
inhibitor following primary PCI, but indicate that earlier
discontinuation may be considered in patients at high risk
of bleeding.22 While limited by the observational nature of the
study and relatively small number of events, our ﬁndings lend
support to these Class IIb recommendations (which were
based on limited data) by showing no excess ischemic risk in
Figure 3. Patient-reported reasons for early prasugrel cessation (crossover, physician-recommended
discontinuation, and disruption). OAC indicates oral anticoagulation.
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patients who discontinued prasugrel or changed to a less-
potent agent based on justiﬁed medical decision (presumably
related, at least in part, to higher bleeding risk). Along the
same lines, a focused guideline update by the European
Society of Cardiology recommended that in patients with ACS
at high risk of bleeding, discontinuation of P2Y12-inhibitor
therapy after 6 months post-stenting should be considered,
as the risk of ischemic complication is highest immediately
after the index event and then gradually declines.23 These
recommendations were based on studies including primarily
non-ST segment elevation–ACS patients treated with
clopidogrel,24 and the need for further studies focusing on
novel P2Y12 inhibitors was explicitly acknowledged.23 Prop-
erly designed prospective studies are needed to assess
tailored approaches for deﬁning the potency and duration of
antiplatelet therapy following STEMI, accounting for individual-
patient bleeding and ischemic risk.
The TROPICAL ACS (Testing Responsiveness To Platelet
Inhibition On Chronic Antiplatelet Treatment For Acute
Coronary Syndromes) randomized trial recently showed that
platelet function-guided de-escalation of prasugrel to clopi-
dogrel 14 days after hospital discharge was noninferior to 1-
year treatment with prasugrel in terms of net clinical beneﬁt in
patients with ACS.25 In the TOPIC (Timing of Platelet Inhibition
After Acute Coronary Syndrome) randomized study (including
646 ACS patients, 40% with STEMI), de-escalation of prasug-
rel or ticagrelor to clopidogrel 1 month post index event was
superior to 1-year treatment with a potent agent for
prevention of bleeding complications, without increase in
ischemic events.26 In the present observational analysis, we
found no increase in ischemic events following crossover
(including primarily de-escalation to clopidogrel and occurring
at a median of 31 days post index PCI) compared with
continued prasugrel treatment throughout 1 year.
The TRANSLATE-ACS registry reported early cessation of
clopidogrel or prasugrel in 21% of STEMI or NSTE-ACS
patients within 1-year post PCI.27 Notably, that registry did
not capture crossover, although this is not uncommon in
clinical practice among patients treated with potent antiplate-
let agents and was in fact the most common mode of
prasugrel cessation in our analysis. Thienopyridine cessation
(not including crossover) was substantially more common in
TRANSLATE ACS compared with the present study (21%
versus 6.3%, ie, the sum of discontinuation and disruption in
our study). Whether this difference might reﬂect variations in
practice patterns in the United States versus Europe (as
suggested, for example, by considerable differences in the use
of bare-metal stent versus DES in the 2 studies) or relate to
more contemporary treatment patterns in the present anal-
ysis (enrollment extended up to 2014 versus 2012 in
Table 4. Incidence of Adverse Clinical Events Within 1 Year
No Cessation
(n=1578)
Crossover
(n=131)
Discontinuation
(n=67)
Disruption
(n=54)
Primary end point 65 (4.1) 13 (9.9) 9 (13.4) 8 (14.8)
Secondary end point 100 (6.3) 21 (16.1) 12 (17.9) 9 (16.7)
Death 26 (1.6) 1 (0.8) 2 (3.0) 5 (9.3)
Cardiac death 23 (1.5) 1 (0.8) 2 (3.0) 4 (7.5)
Myocardial infarction 40 (2.5) 8 (6.1) 3 (4.5) 5 (9.3)
Spontaneous MI 16 (1.0) 5 (3.8) 1 (1.5) 3 (5.7)
Death or MI 63 (4.0) 9 (6.9) 5 (7.6) 6 (10.9)
Stroke 5 (0.3) 4 (3.1) 4 (6) 2 (3.8)
TVR 63 (4.0) 10 (7.7) 7 (10.5) 5 (9.4)
Definite stent thrombosis 25 (1.6) 3 (2.3) 2 (3.0) 4 (7.6)
BARC 3 to 5 bleeding 41 (2.6) 14 (10.7) 5 (7.5) 6 (11.5)
BARC 3 40 (2.6) 11 (8.4) 4 (6) 6 (11.5)
BARC 4 0 (0.0) 3 (2.3) 1 (1.5) 0 (0.0)
BARC 5 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
TIMI major bleeding 21 (1.3) 11 (8.4) 3 (4.5) 5 (9.6)
TIMI minor bleeding 21 (1.3) 3 (2.3) 3 (4.5) 0 (0.0)
Counted are ﬁrst events per event type per patient (% from Kaplan–Meier estimate). Cumulative incidence within 1 year following index PCI is presented, regardless of event occurrence
before or following prasugrel cessation in patients with crossover, discontinuation, or disruption. Primary end point was a composite of cardiac death, nonfatal MI, and stroke. Secondary
end point was a composite of cardiac death, MI, stroke, TVR, and deﬁnite or probable stent thrombosis. BARC indicates Bleeding Academic Research Consortium; MI, myocardial infarction;
PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction; TVR, target vessel revascularization.
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Figure 4. Risk of clinical outcomes following early prasugrel cessation: crossover (n=131); discontinuation (n=67); and disruption (n=54).
Results of time-dependent Cox model analyses for the risk of the primary and secondary end points. Presented are numbers of observed
events (from Kaplan–Meier estimate), hazard ratios (HRs), and respective 95% conﬁdence intervals (CI). The observed vs expected number of
events are presented for each period, where expected numbers were calculated as number of events divided by the HR (compared with the
reference of being on prasugrel treatment). The primary end point was a composite of cardiac death, nonfatal myocardial infarction (MI), and
stroke. Secondary end point was a composite of cardiac death, MI, stroke, target-vessel revascularization (TVR), and deﬁnite or probable stent
thrombosis.
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TRANSLATE-ACS) cannot be deﬁnitively addressed. Of note,
real-world observations indicate greater acceptance rates and
a steady increase in the use of prasugrel over time.5,28 Any
thienopyridine cessation was associated with an increased
risk of major adverse cardiac events in TRANSLATE ACS,27
which contrast with our present ﬁndings in a STEMI cohort as
well as the ﬁndings of the PARIS registry6 in a broader PCI
population.
This study has several limitations. First, the study was not
designed to evaluate clinical outcomes in relation to prasugrel
treatment; however, adverse events were prospectively
deﬁned outcome measures and were speciﬁcally evaluated
during 1-year follow-up in all 3 studies, and adherence to
medical treatment was assessed at predeﬁned time-points
applying standardized deﬁnitions. Second, the present cohort
pooled patients from 2 prospective, all-comers registries and a
randomized STEMI trial. However, the COMFORTABLE-AMI trial
had a broadly inclusive design withminimal exclusion criteria; in
addition, identical follow-up procedures and independent
clinical event adjudication were applied in the randomized trial
as in the registries, thereby minimizing patient heterogeneity in
the present pooled cohort. Although some differences in study
design and patient characteristics did exist, our sensitivity
analyses focusing only on registry patients (Figure S2) showed
consistent outcomes as in the entire pooled population.
Despite the sizable STEMI cohort, this study may be under-
powered to assess clinical outcomes in relation to different
modes of prasugrel cessation; in particular, discontinuation
was associated with a numerically (1.6-fold) higher risk ofmajor
adverse cardiac events, which nonetheless did not reach
statistical signiﬁcance, likely because of the small numbers of
patients and limited numbers of events in each group. Unlike
the PARIS study,6 the exact timing of possible prasugrel re-
initiation was not consistently captured in this study; therefore,
temporary interruptions (eg, before surgery) could not be
deﬁned separately but were included under physician-deter-
mined discontinuation. While the association between prasug-
rel cessation and subsequent events is substantiated by being
derived from time-varying analyses, the fact that no other
covariates were considered is acknowledged as a limitation.
Finally, the ﬁndings of this observational study are presented as
hypothesis-generating only; prospective, adequately powered
studies are required to assess outcomes in relation to shorter
than currently recommended prasugrel treatment duration in
the high-risk setting of STEMI.
Conclusions
Prasugrel cessation was observed in 1 of 7 patients with
STEMI within 1 year following primary PCI in this contempo-
rary study. Early cessation involved primarily change to
another P2Y12-inhibitor and was predicted by clinical charac-
teristic portending higher bleeding risk. Prasugrel disruption
(because of bleeding, side effects, or noncompliance) was
associated with a statistically signiﬁcant, 3-fold higher risk of
major ischemic events.
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Eligibility criteria for the Bern PCI Registry  
All patients undergoing clinically indicated percutaneous coronary intervention (PCI) (for stable 
coronary artery disease, silent ischemia, ST-elevation myocardial infarction [STEMI], non-ST-elevation 
myocardial infarction [NSTEMI], or unstable angina [UA]) at Bern University Hospital, Switzerland as 
of January 2009 are prospectively entered into the ongoing Bern PCI Registry. There are no formal 
exclusion criteria, and all patients who provided informed consent were included in this registry (1-3).  
 
Eligibility criteria for the SPUM ACS registry  
Female and male patients aged 18 years and older presenting within 5 days (preferably 72 hours) 
after pain onset with the main diagnosis of STEMI, NSTEMI, or unstable angina were included in the 
registry (4,5). Included patients had symptoms compatible with angina pectoris (chest pain, dyspnea) 
and fulfilled at least one of the following criteria: (i.) persistent ST-segment elevation or depression, T 
inversion or dynamic ECG changes, new left bundle branch block; (ii.) evidence of positive troponin 
with rise and/or fall in serial troponin levels; (iii.) known coronary artery disease (specified as status 
after myocardial infarction, coronary artery bypass graft surgery, or PCI) or newly documented ≥ 50% 
stenosis of an epicardial coronary artery during the initial catheterization. Exclusion criteria were severe 
physical disability, inability to comprehend study, and estimated life expectancy less than 1 year (due 
to non-cardiac reasons).   
The present analysis included all patients from the Bern PCI Registry and SPUM ACS cohort 
who were enrolled between October 2009 (clinical approval of prasugrel in Switzerland) and June 2014 
with main diagnosis of STEMI and were discharged on prasugrel.   
 
Eligibility criteria for the COMFORTABLE AMI trial  
Consecutive patients aged 18 years or older with acute ST-segment elevation of at least 1 mm 
in two or more contiguous leads, true posterior myocardial infarction or new left bundle branch block 
  
were eligible for randomization in the presence of at least one culprit lesion in the infarct vessel (6-8). 
Exclusion criteria were presence of mechanical complications of acute myocardial infarction, known 
allergy to any study medication, use of vitamin K-antagonists, planned surgery unless dual anti-platelet 
therapy could be maintained throughout the peri-surgical period, history of bleeding diathesis or known 
coagulopathy, pregnancy, participation in another trial before reaching the primary endpoint, inability 
to provide informed consent, and non-cardiac co-morbid conditions with life expectancy below 1 year. 
 
Definition of myocardial infarction  
The diagnosis of spontaneous (>48 hours post index event) Q-wave myocardial infarction 
required new pathological Q waves in two or more contiguous ECG leads. The diagnosis of spontaneous 
non-Q wave MI required documented biomarker elevations consisting of 1) CK-MB >1*URL, or 2) in 
the absence of CK-MB, standard troponin elevations >1*URL, or 3) in the absence of standard troponin 
high sensitivity troponin>1*URL. The appropriate enzyme data were considered in aggregate with 
clinical parameters suggesting evidence of myocardial ischemia based on symptoms, 
electrocardiographic changes, cardiac imaging findings or new regional wall motion abnormalities.  
Peri-procedural myocardial infarction was adjudicated according to three scenarios as described 
below:   
(A) CK (or CK-MB) from index MI had not yet reached its maximum level: Recurrent thoracic chest 
pain or ischemia equivalent >20 minutes (or new ECG changes consistent with MI) and biomarker data:  
1) A rise in CK within 24 hours of the event >2*URL (confirmed by either CK-MB or troponin > 
1*URL) and  50% above the previous level or,  
2) in absence of CK: a (post PCI) rise in CK-MB within 24 hours of the event >3*URL and  50% 
above the previous level, or  
3) in absence of CK and CK-MB: a (post PCI) rise of troponin within 24 hours of the index event 
>3*URL and   50% above the previous level.  
(B) Elevated CK (or CK-MB) following the index MI had peaked AND CK level has returned < URL 
then any new rise in:  
1) CK >2*URL (confirmed by either CK-MB >URL or troponin >URL), or  
  
2) in the absence of CK a rise of CK-MB >3*URL, or  
3) in the absence of CK and CK-MB, a troponin rise >3*URL. 
(C) CK (or CK-MB) following the index MI had peaked AND CK level has NOT returned <URL:  
1) a rise in CK  50% above the previous level and >2 URL confirmed by either CK-MB >URL or 
troponin >URL, or  
2) in absence of CK, when CK-MB has NOT returned to <URL, a rise in CK-MB  50% above the 
previous level and > 3 URL, or  
3) in absence of CK, when CK-MB and troponin had not returned to <URL a rise in troponin  
50% above the previous level and >3*URL.  
 
  
  
Table S1. Status of follow-up at 1 year after PCI.   
  
All patients 
n = 1,830 
No cessation 
N = 1,578 
Crossover 
n = 131 
Discontinuation 
n = 67 
Disruption 
n = 54 
Outcome at 1 year 
     
Alive: follow-up performed 1,793 (98.0%) 1,549 (98.2%) 130 (99.2%) 64(97%) 50 (90.7%) 
Alive: refuses follow-up  1 (0.1%) 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 
Alive: follow-up not performed 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Patient dead 34 (1.9%) 26 (1.6%) 1 (0.8%) 2 (3%) 5 (9.3%) 
Untraceable  2 (0.1%) 2 (0.1%) 0 (0%) 0  (0%) 0  (0%) 
 
  
 
 
  
  
Table S2. Medications at discharge and 1 year after PCI.   
  Overall 
n = 1,830 
No cessation 
n = 1,578 
Crossover 
n = 131 
Discontinuation 
n = 67 
Disruption 
n = 54 
p Values (vs. No cessation) 
  Crossover Discontinuation  Disruption 
At discharge, n (%)                 
Acetylsalicylic acid 1828 (99.9) 1576 (99.9) 131 (100) 67 (100) 54 (100) 1.00 1.00 1.00 
Prasugrel 1830 (100) 1578 (100) 131 (100) 67 (100) 54 (100)       
Oral anticoagulation 29 (1.6) 23 (1.5) 1 (0.8) 4 (6) 1 (1.9) 1.00 0.02 0.56 
B-blocker 1574 (86.1) 1370 (86.9) 101 (77.1) 61 (91) 42 (77.8) 0.004 0.46 0.07 
ACE inhibitor / ARB 1552 (84.9) 1337 (84.8) 109 (83.2) 60 (89.6) 46 (85.2) 0.61 0.38 1.00 
Statin 1793  (98.0) 1546 (98.0) 129 (98.5) 65 (97) 53 (98.1) 1.00 0.39 1.00 
At 1 year, n (%)                 
Acetylsalicylic acid 1755/1791 (98.0) 1528/1547 (98.8) 123 (94.6) 62/65 (95.4) 42/49 (85.7) 0.003 0.06 <0.001 
Prasugrel* 1477/1791 (82.5) 1458/1547 (94.2) 7 (5.4) 7/65 (10.8) 5/49 (10.2) <0.001 <0.001 <0.001 
Clopidogrel* 167/1791 (9.3) 53/1547 (3.4) 108 (83.1) 1/65 (1.5) 5/49 (10.2) <0.001 0.72 0.03 
Ticagrelor* 13/1791 (0.7) 2/1547 (0.1) 11/130 (8.5) 0/65 (0) 0/49 (0) <0.001 1.000 1.000 
Any dual antiplatelet therapy* 1617/1791 (90.3) 1484/1547 (95.9) 118/130 (90.8) 8/65 (12.3) 7/49 (14.3) 0.013 <0.001 <0.001 
Oral anticoagulation 58/1790 (3.2) 23/1546 (1.5) 14/130 (10.8) 18/65 (27.7) 3/49 (6.1) <0.001 <0.001 0.04 
B-blocker 1473/1789 (82.3) 1293/1546 (83.6) 104/130 (80.0) 50/64 (78.1) 26/49 (53.1) 0.27 0.23 <0.001 
ACE inhibitor / ARB 1135/1788 (63.5) 1011/1545  (65.4) 73 (56.2) 36/64 (56.3) 15/49 (30.6) 0.04 0.14 <0.001 
Statin  1666/1788 (93.2) 1456/1545 (94.2) 123/130 (94.6) 58/64 (90.6) 29/49 (59.2) 1.00 0.27 <0.001 
    
*330 days or more was accepted as compliant.  
ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker.  
 
  
  
Table S3. Baseline sociodemographic characteristics.   
  Overall  
n = 1,830 
No cessation 
n = 1,578 
Crossover 
n = 131 
Discontinuation 
n = 67 
Disruption 
n = 54  
p Value (vs. No cessation) 
Crossover Discontinuation Disruption 
Professional situation n = 638 n = 544 n = 51 n = 24 n = 19 0.13 0.07 0.38 
Full time 339 (53.1) 298 (54.8) 21 (41.2) 8 (33.3) 12 (63.2) 0.08 0.06 0.64 
Part time 64 (10.0) 54  (9.9) 5  (9.8) 2 (8.3) 3 (15.8) 1.00 1.00 0.43 
No employment/retired 235 (36.8) 192 (35.3) 25 (49.0) 14 (58.3) 4 (21.1) 0.07 0.03 0.23 
Education level n = 599 n = 516 n = 44 n = 21 n = 18 0.72 0.95 0.96 
Low education level 86 (14.4) 77 (14.9) 4  (9.1) 3 (14.3) 2 (11.1) 0.37 1.00 1.00 
Appreticeship / vocational school 371 (61.9) 316 (61.2) 30 (68.2) 13 (61.9) 12 (66.7) 0.42 1.00 0.81 
High school  67 (11.2) 57 (11.0) 5 (11.4) 3 (14.3) 2 (11.1) 1.00 0.72 1.00 
University  75 (12.5) 66 (12.8) 5 (11.4) 2 (9.5) 2 (11.1) 1.00 1.00 1.00 
Marital status n = 671 n = 570 n = 54 n = 26 n = 21 0.98 0.73 0.05 
Married 458 (68.3) 392 (68.8) 38 (70.4) 16 (61.5) 12 (57.1) 0.88 0.52 0.34 
Divorced 96 (14.3) 80 (14.0) 8 (14.8) 3 (11.5) 5 (23.8) 0.84 1.00 0.21 
Widowed 25  (3.7) 21  (3.7) 2  (3.7) 2 (7.7) 0 (0) 1.00 0.26 1.00 
Single 68 (10.1) 58 (10.2) 5  (9.3) 4 (15.4) 1 (4.8) 1.00 0.33 0.71 
Partnership 24  (3.6) 19 (3.3) 1 (1.9) 1 (3.8) 3 (14.3) 1.00 0.60 0.04 
Living arrangement n = 657 n = 560 n = 52 n = 25 n = 20 0.65 0.86 0.69 
Living alone 123 (18.7) 104 (18.6) 11 (21.2) 5 (20) 3 (15) 0.71 0.80 1.00 
Living with someone 534 (81.3) 456 (81.4) 41 (78.8) 20 (80) 17 (85) 0.71 0.80 1.00 
 
Data only available for patients included in the SPUM-ACS registry.  
 
  
Table S4. Univariable predictors of any prasugrel cessation. 
  Sample size Hazard ratio (95% CI) p Value 
Age (per 10 years) n = 1830 1.18 (1.05-1.32) 0.005 
Female sex n = 1830 1.80 (1.35-2.38) <0.001 
Body mass index (per 10 units) n = 1765 0.69 (0.50-0.96) 0.03 
Diabetes mellitus n = 1826 0.67 (0.44-1.03) 0.07 
History of cerebrovascular accident n = 1826 3.26 (1.34-7.89) 0.009 
Clinically relevant valvular disease n = 1161 3.78 (0.94-15.24) 0.06 
Previous CABG n = 1826 0.24 (0.03-1.73) 0.16 
Time from symptom onset to balloon inflation >24h n = 1811 1.37 (0.93-2.01) 0.11 
Resuscitation before hospital arrival n = 1161 0.19 (0.03-1.34) 0.09 
LVEF (per 10%) n = 1625 0.91 (0.81-1.02) 0.11 
COPD n = 1826 1.57 (0.81-3.05) 0.18 
Multivessel treatment n = 1826 1.31 (0.92-1.88) 0.13 
Long lesion (any total stent length ≥20mm) n = 1220 1.26 (0.89-1.78) 0.19 
SYNTAX MI score n = 479 1.29 (0.95-1.76) 0.11 
    
        
CABG indicates coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; LVEF, left 
ventricular ejection fraction.  
 
 
  
  
Table S5. Summary of individual primary-endpoint events following early prasugrel cessation. 
  
Age 
(years) 
Sex Time from baseline 
to cessation (days) 
Time from cessation 
to event (days) 
Clinical event    
I. Crossover  
48 Female 4 4 Patient changed from prasugrel to clopidogrel due to 
CABG operation. A cerebrovascular event occurred 
before the operation, 4 days after change to 
clopidogrel.  
62 Male 35 7 Patient changed from prasugrel to clopidogrel 4 days 
prior to elective CABG surgery. A cerebrovascular 
event occurred 3 days after CABG surgery.  
43 Female 98 8 Patient changed from prasugrel to clopidogrel 
because of menorrhagia. A non-Q-Wave myocardial 
infarction requiring PCI occurred after 8 days.   
60 Male 15 10 Patient changed from prasugrel to clopidogrel due to 
CABG operation, during which the patient suffered 
a cerebrovascular event.   
86 Male  302 42 Patient changed from prasugrel to clopidogrel due to 
a rib fracture with BARC 2 bleeding. A 
cerebrovascular event occurred 6 weeks thereafter.  
56 Male 9 142 Patient changed from prasugrel to clopidogrel 
because of initiation of oral anticoagulation. Patient 
died suddenly (cardiac death, exact cause unknown).  
80 Male 29 314 Patient changed from prasugrel to clopidogrel  due 
to financial reasons. A non-Q-Wave myocardial 
infarction and TIA occurred after 314 days.   
II.  Discontinuation   
     
80 Male 185 4 Prasugrel was stopped prior to elective CABG 
operation, during which the patient suffered a 
myocardial infarction. 
45 Male 216 9  Prasugrel was stopped because patient received 
palliative treatment due to metastatic lung cancer. 
Patient died 9 days later.   
69 Male 265 61 Patient stopped prasugrel because of initiation of 
oral anticoagulation due to a pulmonary embolism. 
A stroke occurred 2 months thereafter.   
71 Male 163 104 Prasugrel was stopped because of initiation of oral 
anticoagulation >5 months after index event. Patient 
died suddenly (cardiac death, exact cause unknown).    
III.  Disruption 
66 Male 23 5 Patient decided to stop prasugrel.  Myocardial 
infarction due to stent thrombosis occurred after 5 
days. 
  
    
 
  
53 Male 22 7 Patient stopped taking prasugrel (personal decision) 
early after discharge and had a myocardial infarction 
1 week later. 
59 Female 68 7 Patient stopped prasugrel because of financial 
reasons and had a stent thrombosis 1 week later.  
55 Female 82 10 Patient stopped prasugrel due to financial reasons 
early after discharge. Myocardial infarction due to 
stent thrombosis occurred after 10 days.  
50 Male 195 132 Patient stopped prasugrel on own initiative and had a 
stent thrombosis 4 months later.   
84 Male 24 235 Patient stopped prasugrel due to perceived side 
effect (gastric intolerance). Sudden cardiac death 
occurred after >7 months.   
  
Table S6. Baseline clinical characteristics in patients enrolled in the COMFORTABLE AMI 
randomized trial vs. the observational registries (Bern PCI Registry and SPUM-ACS 
study).  
 
  Randomized trial  
n=484 
Observational registries 
n=1,346 
p Value 
Age 59.2 ± 10.7 59.2 ± 11.0 0.98 
BMI 27.5 ±  4.1 27.3 ±  4.3 0.36 
Current smoking 227 (47.1%) 635 (48.0%) 0.75 
Hyperlipiemia 263 (54.9%) 672 (50.3%) 0.09 
Hypertension 223 (46.1%) 617 (46.0%) 1.00 
Diabetes mellitus 63 (13.0%) 172 (12.8%) 0.94 
Family history of CAD  118 (24.6%) 344 (25.9%) 0.58 
Renal dysfunction* 36  (7.7%) 99  (8.6%) 0.62 
Renal insufficiency requiring    
   dialysis 
0 (0.0%) 3 (0.2%) 0.57 
Peripheral artery disease 5  (1.0%) 33  (2.5%) 0.07 
History of cerebrovascular accident 3  (0.6%) 11  (0.8%) 1.00 
Previous PCI 22  (4.5%) 129  (9.6%) <0.001 
Previous CABG 9  (1.9%) 19  (1.4%) 0.52 
Time from symptom onset to  
    balloon inflation (min)  
237 (161; 412) 225 (155; 390) 0.094 
Killip class IV at presentation 3  (0.6%) 84  (6.3%) <0.001 
History of gastrointestinal bleeding 3 (0.6%) 10 (0.7%) 1.00 
History of malignancy 16  (3.3%) 64  (4.8%) 0.20 
 
Data are summarized as mean ± standard deviation, median (25%-75% interquartile range) or count 
(%).  
*Defined as estimated glomerular filtration rate <60 ml/min/1,73m² using the Cockcroft-Gault formula.  
 
BMI indicates body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; 
LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.     
 
 
 
  
  
Table S7. Frequency of crossover, discontinuation and disruption of prasugrel in 
patients enrolled in the COMFORTABLE AMI randomized trial vs. the 
observational registries (Bern PCI Registry and SPUM-ACS study). 
 
  
Overall 
N=1,830 
Randomized trial 
n=484 
Registries 
n=1,346 
p Value 
No cessation 1578 (86.2%) 428 (88.4%) 1,150 (85.4%) 0.23 
Crossover 131  (7.2%) 24  (5.0%) 107 (7.9%) 0.09 
Discontinuation 67  (3.7%) 14  (2.9%) 53 (3.9%) 0.57 
Disruption  54  (3.0%) 18  (3.7%) 36 (2.7%) 0.33 
 
  
  
Figure S1. Risk of bleeding in relation to early prasugrel cessation: crossover (n=131); 
discontinuation (n=67); and disruption (n=54). Presented are numbers of observed events (from 
Kaplan-Meier estimate), expected events, hazard ratios and respective 95% confidence intervals (CI).   
 
 
 
 
  
Figure S2. Results of time-dependent Cox model analyses for the risk of adverse clinical outcomes 
following early prasugrel cessation (crossover: n=107; discontinuation; n=53; disruption: n=36) 
in a sensitivity analysis including only patients enrolled in the observational registries (Bern PCI 
Registry and SPUM-ACS study; n=1,346). Presented are numbers of observed events (from Kaplan-
Meier estimate), expected events, hazard ratios (HRs) and respective 95% confidence intervals (CI).  
The observed versus expected number of events are presented for each period, where expected numbers 
were calculated as number of events divided by the HR (compared to the reference of being on prasugrel 
treatment). 
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